Thomas J. Semrad, MD, assistant professor, co-director, Phase I Program, UC Davis Health System, discusses the Serial Patient-Derived Xenografts to Understand Cancer Therapy Resistance (SPIDER) program at UC Davis Health System, aimed at understanding patient resistance to cancer therapies.
Moon S. Chen Jr., PhD, MPH, associate director, Population Research and Cancer Disparities, professor, UC Davis Comprehensive Cancer Center, discusses various disparities in cancer care in underserved populations.
Megan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.
Jeanine Stiles, chief administrative officer, associate director for administration, UC Davis Comprehensive Cancer Center, discusses the importance of supportive care for patients with cancer.
Clinical trial designs are undergoing a dramatic transformation geared toward the discovery and validation of new predictive biomarkers.
A number of clinical trials are now assessing PD-1 and PD-L1 inhibitors in combination with chemotherapy, targeted therapies, and radiation therapy in an attempt to further improve outcomes for patients with non–small cell lung cancer.
The rise of oral anticancer agents is revolutionizing cancer treatment for both patients and cancer care providers. Patients can take their medications in the comfort of their own homes without the need for needles, long stints in infusion chairs or intensive nursing oversight.
David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.